ClinicalTrials.gg
CompletedNCT01657851Updated Jun 20, 2017

Bioequivalence - Duodart Against Avodart & Omnic

A Phase 1 interventional study of dutasteride/tamsulosin and dutasteride in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Completed at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing dutasteride in Prostatic Hyperplasia — 1 open to participants now, 1 under way, none of them phase 3. Dutasteride · Prostatic Hyperplasia.

Enrollment
18th of 27
35 · median 44
Started
2012
with 1 other
Phase 1
8 of 27
none open now
Registered
22nd of 27
by date
Lead sponsor
15 of 27
GlaxoSmithKline

Among the 27 studies testing dutasteride in Prostatic Hyperplasia, this one is the 18th largest by enrollment, is one of 2 that started in 2012, is one of 8 in phase 1, and was the 22nd registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

1 of the 27 studies testing dutasteride in Prostatic Hyperplasia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dutasteride

Dutasteride: first FDA approval 2001 (AVODART). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing dutasteride in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Open-label, randomized, single dose, two-treatment, two-way crossover study

Read the detailed description

The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia. The design of the present study relies on data obtained in pivotal bioequivalence study and Russian guidance on high quality bioequivalence studies.

Summary of treatment groups Treatment Sequence Number of subjects

  1. 18
  2. 18 Total number of subjects 36 Eligible subjects will be admitted to the research unit one day prior to dosing (Day 0) and will remain as inpatients until approximately 72 hours after dosing. Subjects will undergo a washout period of approximately 28 days from each dose of study medication. During washout period subjects will be contacted via telephone within approximately 10-14 days after the dosing for the collection of information about adverse events and medications taken by volunteers during washout period Overall study duration could be about 2 months - Screening up to 21 days + 10 days (5 days of each of 2 treatment periods) + 28 days washout period between treatment administration + 10-14 days of follow up period.

Upon completion of the last dosing session, subjects will be contacted via telephone within approximately 10-14 days for a follow-up inquiry (or visit at the discretion of the investigator) and will be subsequently discharged from the study.

  • Order of Assessments and Procedures

Where multiple measurements/evaluations are scheduled for the same time then the measurements/evaluations will be taken in the following order:

  1. Vital Signs
  2. Orthostatic Vital Signs
  3. PK - Blood Sample Where multiple measurements/evaluations are scheduled for the same time then the study co-coordinator will attempt to ensure that the PK samples are drawn as close to the scheduled time as possible whilst adhering to the order of assessments as described above.

    • Blinding and Randomisation On Day 0 of the first treatment period, subjects will be randomly allocated at the ratio of 1:1 to one of 2 treatments (refer to Table 1), according to a computer-generated randomisation list. CRO will generate the randomisation list. For the purpose of randomisation screening numbers of volunteers will be used; randomisation numbers will not be assigned to study subjects.

Treatment will be open-label; therefore, blinding procedures are not applicable.

  • Number of Subjects Approximately 50 healthy male subjects will be screened to allow 36 eligible subjects to be randomized and ensure that 30 subjects complete the study according to the protocol without violations.
  • PHARMACOKINETIC PARAMETERS
  • Drug assay Dutasteride and tamsulosin will be extracted from human plasma by liquid-liquid extraction using organic solvent. Extracts will be analysed by validated high-performance liquid chromatography - mass spectrometry. The lower limit of detection is about 0.1ng/mL
  • Calculation of Pharmacokinetic Parameters Pharmacokinetic parameters will be computed for each subject and treatment using standard methods as described in Appendix II.

For tamsulosin, the following PK parameters will be computed:

  • Cmax
  • Tmax
  • AUC(0-t)
  • AUC(0-∞)
  • Half-life
  • Mean residence time

For dutasteride, the following PK parameters will be computed:

  • Cmax
  • Tmax
  • AUC(0-t)
  • Mean residence time The half-life and AUC(0-∞) will be computed only for tamsulosin because duration of sampling period equal to 72 h is expected to be non-sufficient for reliable computation of half-life and AUC(0-∞) of dutasteride given the complex pharmacokinetics of dutasteride and long half-life of dutasteride at each of two elimination pathways [12].

    • ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE) The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE.

AEs will be collected from the start of Study Treatment and until the follow-up contact.

SAEs will be collected over the same time period as stated above for AEs. However, any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product will be recorded from the time a subject consents to participate in the study up to and including any follow-up contact. All SAEs will be recorded and reported to GSK within 24 hours

  • LIFESTYLE AND/OR DIETARY RESTRICTIONS
  • Meals and meal composition Subjects will be required to fast for approximately 10 hours prior to dosing, with the exception of water, which will be allowed freely except for 1 hour before and 1 hour after dosing.

Following dosing, subjects will not be allowed food until 4 hours post dose. Meals will be served at the times outlined in Section 2 (Schedule of Assessments), in a seated position (unless orthostasis detected, in which meals should be served in a semi-recumbent position).

Meals will be served on Days 2 and 3 at approximately the same time as on Day 1.

Subjects will not be allowed to consume the following foods or drinks within 7 days prior to the first dose of study medication until after collection of the final pharmacokinetic blood sample: grapefruit juice; red wine; grapefruit or cruciferous vegetables (watercress, broccoli, cabbage, Brussels sprouts).

  • Dosage and Administration One Duodart® 0.5mg/0.4mg capsule as Test formulation or one Avodart® 0.5 mg and one Omnic® 0.4 mg capsules as Reference formulation will be administered in the morning of Day 1 in each study period. The capsules should not be opened or chewed, but swallowed whole with 200 mL of water at room temperature
  • STATISTICAL METHODS
  • Population for analysis For pharmacokinetics parameters calculation and statistical analysis, the data received from no less than 30 volunteers who have completed the study according to the Protocol will be explored.

Safety analysis population of this study will consist of all volunteers who took part in at least one study stage.

Data from volunteers who discontinued the study prematurely will be included in the final report, but no included in the pharmacokinetics parameters calculation and statistical analysis.

If the volunteer has not taken any of the study drugs at all, his/her data are not to be included in the statistical analysis.

  • Analysis Method For pharmacokinetics parameters calculation, statistical analysis, and results presentation statistical packages (Statistics, Microsoft Excel 2007, SAS, or SPSS) will be used.

Descriptive statistics will be used to present the mean value, standard deviation, median value, minimal and maximal value.

Analysis of variance will be done based on the assumption about the log-normal distribution of AUC, Cmax, and Cmax/AUC, and normal distribution of other pharmacokinetics parameters except tmax. The comparison of average values of the investigated and comparator drug parameters is performed with the multiplicative model as a basis and confidence intervals built for the ratio of the corresponding mean values. After the logarithmic transformation these values will be analyzed by analysis of variance (ANOVA).

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give written
  • Males who are 18 - 45 years of age, inclusive
  • Verified diagnosis "healthy"
  • 20-25 kg/m2 (inclusive)
  • Negative results of test for , syphilis, (HBs Ag) and
  • Adequate, liver, and renal function
  • adequate

Exclusion criteria

Exclusion Criteria:

  • Poor metabolizer for CYP2D6
  • Medical history of allergy
  • Medical history of medicines intolerability
  • Chronic diseases
  • History of surgery on gastrointestinal tract
  • History of prostate cancer
  • History of breast cancer
  • Acute infectious disease
  • Regular use of drugs
  • Intake of medicines with high influence on liver function or haemodynamics
  • Use of drugs that influence activity of CYP2D6 and
  • Use of Dutasteride less than 6 months before study entry or alpha-blockers less than 2 weeks before study entry
  • Blood donation (≥450 mL of blood or plasma) less than 2 months before study start
  • History of regular alcohol consumption
  • A positive urine drug or alcohol
  • Smoking more than 10 cigarettes a day
  • Participation in Phase I clinical trials less than 3 months before study entry
  • History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal reactions or any other signs and symptoms of orthostasis
  • Subjects who have consumed the following foods or drinks within 7 days prior to the first dose of study medication or at any time during the clinical phase of the study: grapefruit juice; red wine; grapefruit or cruciferous vegetables (watercress, broccoli, cabbage, Brussels sprouts).
  • ≥ 450 msec at screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    dutasteride/tamsulosin

    The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.

    Drug: dutasteride/tamsulosin

  • Active comparator
    dutasteride

    Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.

    Drug: dutasteride · Drug: tamsulosin

  • Active comparator
    tamsulosin

    Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia

    Drug: dutasteride · Drug: tamsulosin

Interventions

  • Drugdutasteride/tamsulosin

    Drug pages: Dutasteride · Tamsulosin

    Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

    Also known as: Duodart® 0.5 mg / 0.4 mg

  • Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

    Also known as: Avodart® 0.5 mg

  • Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

    Also known as: Omnic® 0.4 mg

06

What researchers measure

Primary outcomes

  1. bioequivalence of a Combination Capsule formulation of dutasteride 0.5 mg/ tamsulosin HCl 0.4 mg (Duodart® 0.5 mg/ 0.4 mg fixed combination) relative to concomitant dosing of Avodart® 0.5 mg and the Omnic® 0.4

    Dutasteride and tamsulosin will be extracted from human plasma by liquid-liquid extraction using organic solvent. Extracts will be analysed by validated high-performance liquid chromatography - mass spectrometry. The lower limit of detection is about 0.1ng/mL

    Time frame: 2 months

Secondary outcomes

  1. to evaluate the safety and tolerability of the Combination Capsule formulation of dutasteride 0.5 mg/ tamsulosin HCl 0.4 mg

    The following safety parameters will be assessed during the study: Physical examination; Orthostatic vital signs; Vital signs; 12-lead ECG; Adverse events; Serum chemistry; Complete blood count

    Time frame: 2 months

07

Study locations

1 site
  • GSK Investigational Site
    Reutov, Moscow Region, 143964, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Dec 2012, 3 months.

Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's 3 months is close to that.

Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2012
First posted
Aug 6, 2012
StartActual
Aug 23, 2012
Primary completionActual
Dec 5, 2012
CompletionActual
Dec 5, 2012
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01657851
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 6, 2012
Start date
Aug 23, 2012
Primary completion
Dec 5, 2012
Completion
Dec 5, 2012
Last update
Jun 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dutasteride · Tamsulosin

Start the discussion